Contrasting model mechanisms of alanine aminotransferase (ALT) release from damaged and necrotic hepatocytes as an example of general biomarker mechanisms.


Journal

PLoS computational biology
ISSN: 1553-7358
Titre abrégé: PLoS Comput Biol
Pays: United States
ID NLM: 101238922

Informations de publication

Date de publication:
06 2020
Historique:
received: 19 12 2019
accepted: 08 05 2020
revised: 12 06 2020
pubmed: 3 6 2020
medline: 25 8 2020
entrez: 3 6 2020
Statut: epublish

Résumé

Interpretations of elevated blood levels of alanine aminotransferase (ALT) for drug-induced liver injury often assume that the biomarker is released passively from dying cells. However, the mechanisms driving that release have not been explored experimentally. The usefulness of ALT and related biomarkers will improve by developing mechanism-based explanations of elevated levels that can be expanded and elaborated incrementally. We provide the means to challenge the ability of closely related model mechanisms to generate patterns of simulated hepatic injury and ALT release that scale (or not) to be quantitatively similar to the wet-lab validation targets, which are elevated plasma ALT values following acetaminophen (APAP) exposure in mice. We build on a published model mechanism that helps explain the generation of characteristic spatiotemporal features of APAP hepatotoxicity within hepatic lobules. Discrete event and agent-oriented software methods are most prominent. We instantiate and leverage a small constellation of concrete model mechanisms. Their details during execution help bring into focus ways in which particular sources of uncertainty become entangled with cause-effect details within and across several levels. We scale ALT amounts in virtual mice directly to target plasma ALT values in individual mice. A virtual experiment comprises a set of Monte Carlo simulations. We challenge the sufficiency of four potentially explanatory theories for ALT release. The first of the tested model theories failed to achieve the initial validation target, but each of the three others succeeded. Results for one of the three model mechanisms matched all target ALT values quantitatively. It explains how ALT externalization is the combined consequence of lobular-location-dependent drug-induced cellular damage and hepatocyte death. Falsification of one (or more) of the model mechanisms provides new knowledge and incrementally shrinks the constellation of model mechanisms. The modularity and biomimicry of our explanatory models enable seamless transition from mice to humans.

Identifiants

pubmed: 32484845
doi: 10.1371/journal.pcbi.1007622
pii: PCOMPBIOL-D-19-02206
pmc: PMC7292418
doi:

Substances chimiques

Biomarkers 0
Acetaminophen 362O9ITL9D
Alanine Transaminase EC 2.6.1.2

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1007622

Subventions

Organisme : NIGMS NIH HHS
ID : P30 GM118247
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM103549
Pays : United States

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

CPT Pharmacometrics Syst Pharmacol. 2014 Feb 05;3:e98
pubmed: 24500662
JAMA. 2006 Jul 5;296(1):87-93
pubmed: 16820551
J Pharmacol Exp Ther. 2018 Apr;365(1):127-138
pubmed: 29434053
Toxicol Appl Pharmacol. 1999 May 1;156(3):179-86
pubmed: 10222310
Pharm Res. 2009 Nov;26(11):2369-400
pubmed: 19756975
Theor Biol Med Model. 2011 Sep 27;8:35
pubmed: 21951817
Toxicol Appl Pharmacol. 2013 Jun 15;269(3):240-9
pubmed: 23571099
PLoS One. 2016 May 26;11(5):e0155855
pubmed: 27227433
Toxicol Sci. 2019 May 1;169(1):151-166
pubmed: 30698817
Eur J Clin Pharmacol. 2013 Apr;69(4):851-7
pubmed: 23052410
Toxicol Appl Pharmacol. 2012 Nov 1;264(3):387-94
pubmed: 22980195
Theor Biol Med Model. 2012 Aug 31;9:39
pubmed: 22938185
PLoS One. 2018 Sep 13;13(9):e0198060
pubmed: 30212461
Toxicol Sci. 2005 Mar;84(1):201-8
pubmed: 15601672
J Hepatol. 2013 Sep;59(3):495-503
pubmed: 23665281
Can J Physiol Pharmacol. 1989 Sep;67(9):1015-22
pubmed: 2513108
BMC Syst Biol. 2010 Dec 03;4:168
pubmed: 21129207
Genome Res. 2009 Sep;19(9):1507-15
pubmed: 19416960
Drug Metab Dispos. 2008 Apr;36(4):759-68
pubmed: 18227144
Biosystems. 2006 Jul;85(1):37-45
pubmed: 16581178
Sci Rep. 2017 Jan 30;7:37541
pubmed: 28134251
EXCLI J. 2016 Dec 15;15:817-828
pubmed: 28337112
Expert Rev Mol Diagn. 2018 Sep;18(9):797-807
pubmed: 30080986
J Pharmacol Exp Ther. 2015 Aug;354(2):230-7
pubmed: 26065700
PLoS Comput Biol. 2010 Feb 19;6(2):e1000681
pubmed: 20174606
J Clin Invest. 1955 Jan;34(1):126-31
pubmed: 13221663
Redox Biol. 2013 Aug 26;1:427-32
pubmed: 24191236
PLoS Comput Biol. 2016 Dec 16;12(12):e1005253
pubmed: 27984590
Nature. 2017 Feb 16;542(7641):352-356
pubmed: 28166538
Pharm Res. 2008 May;25(5):1023-36
pubmed: 18044012
Wiley Interdiscip Rev Syst Biol Med. 2014 Jul-Aug;6(4):289-309
pubmed: 24810243

Auteurs

Andrew K Smith (AK)

Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California, United States of America.

Glen E P Ropella (GEP)

Tempus Dictum, Inc., Milwaukie, Oregon, United States of America.

Mitchell R McGill (MR)

Department of Environmental and Occupational Health, Fay W. Boozman College of Public Health, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.

Preethi Krishnan (P)

Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California, United States of America.

Lopamudra Dutta (L)

Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California, United States of America.

Ryan C Kennedy (RC)

Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California, United States of America.

Hartmut Jaeschke (H)

Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, United States of America.

C Anthony Hunt (CA)

Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California, United States of America.

Articles similaires

Vancomycin-associated DRESS demonstrates delay in AST abnormalities.

Ahmed Hussein, Kateri L Schoettinger, Jourdan Hydol-Smith et al.
1.00
Humans Drug Hypersensitivity Syndrome Vancomycin Female Male
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
C-Reactive Protein Humans Biomarkers Inflammation

Classifications MeSH